Fortitude Advisory Group’s Integra LifeSciences IART Stock Holding History

Fortitude Advisory Group’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-30	Closed	-$2K	–	678
2022 Q1	$2K	Hold	30	–	–	﹤0.01%	1347
2021 Q4	$2K	Buy	+30	New	+$2.03K	﹤0.01%	1379

Other funds holding IART

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

EVM

Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Fortitude Advisory Group's IART Position: Q2 2022 in Review

Fortitude Advisory Group sold out of Integra LifeSciences (IART) in Q2 2022, closing a stake of 30 shares — an estimated $2K sold.

Fortitude Advisory Group first reported a position in IART in Q4 2021 and held it in 2 quarters. The position peaked at $2K in Q1 2022. 284 funds tracked by Wall St. Rank hold IART as of Q2 2022.

Fortitude Advisory Group reported no remaining Integra LifeSciences position as of Q2 2022 after selling out during the quarter.
Fortitude Advisory Group sold 30 Integra LifeSciences shares in Q2 2022, an estimated $2K.
Fortitude Advisory Group first reported a position in Integra LifeSciences in Q4 2021 and held it in 2 quarters.
Fortitude Advisory Group's Integra LifeSciences position peaked at $2K in Q1 2022.
284 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2022.

Based on Fortitude Advisory Group's 13F filing for Q2 2022, filed 16 Aug 2022.